Latest news with #TAVI
Fashion Value Chain
7 days ago
- Health
- Fashion Value Chain
S.L. Raheja Hospital, Mumbai Completes 50 TAVI Procedures, Showcasing Excellence Minimally Invasive Heart Solutions
This milestone marks a major leap in delivering safer, faster, and more effective heart valve treatment for elderly and high-risk patients, setting high benchmarks for the hospitals Structural Heart Program In addition to its excellence in Cardiology, S.L. Raheja Hospital-a quaternary care center in Mumbai-offers advanced care in Oncology, Neurology, Orthopedics, Critical Care, Diabetology, and other specialties, ensuring comprehensive, patient-centered treatment Clinicians at the Department of Interventional Cardiology and Structural Heart Intervention at S.L. Raheja Hospital, Mahim – A Fortis Associate have successfully performed 50 Transcatheter Aortic Valve Implantation (TAVI) procedures – marking a significant milestone for cardiac care in the Mumbai region. This milestone puts S.L. Raheja Hospital, Mahim, at the forefront of cardiac care in Mumbai, with one of Mumbai's most advanced Structural Heart Programs. The milestone was achieved under the leadership of Dr. Haresh Mehta, Director – Interventional Cardiology and Structural Heart Interventions, along with Consultant – Interventional Cardiologists Dr. Kayan Siodia and Dr. Raghav Nagpal. (L-R) Dr Raghav Nagpal, Dr Haresh Mehta & Dr Kayan Siodia, Interventional Cardiology & Structural Heart Team at S.L. Raheja Hospital, Mumbai – A Fortis Associate TAVI is a minimally invasive procedure used to replace a narrowed Aortic Valve that fails to open properly, a condition known as Aortic Stenosis. It can be potentially life-changing for elderly and high-risk patients who are not suitable for open-heart surgery. Among the 50 procedures performed, the team has successfully navigated many complex cases – including bicuspid aortic valves (typically more challenging due to having two cusps instead of three) and extremely narrow femoral arteries, sometimes as small as 4.95 mm. In rare cases where femoral access was not feasible, the team has also performed trans carotid (neck-access) TAVIs with excellent results – demonstrating both technical expertise and adherence to standardized global best practices. Talking about the benefits of TAVI, Dr. Haresh Mehta, Director – Interventional Cardiology and Structural Heart Interventions, S.L. Raheja Hospital, Mahim – A Fortis Associate, said, 'Severe symptomatic Aortic Stenosis can limit a patient's life expectancy to just 2-to-5 years. Thus, TAVI, the procedure used to treat this condition, can bring about life-altering changes as it extends life, and also dramatically improves quality of life. Since it is minimally invasive, patients often feel relief within 24 hours of the procedure and are discharged within 48 hours – all without the need for open surgery, sutures, or any long recovery times. While TAVI is a key cardiac procedure, patients also benefit from a range of advanced treatments for other heart conditions, including pacemaker implantation, structural heart interventions, and coronary angioplasties.' Talking about the milestone, Dr. Kunal Punamiya, CEO, S.L. Raheja Hospital, Mahim – A Fortis Associate, said, 'This momentous achievement reflects our ongoing commitment to delivering cutting-edge cardiac interventions to those who need it the most. With this milestone, we continue to deliver world-class minimally invasive cardiac care that ensures improved outcomes, faster recovery, and enhanced quality of life. Our Structural Heart Program has been designed to provide cutting-edge cardiac therapies under one roof, which includes stenting and Angioplasty, Atherectomy, ICD and Pacemaker implantation, valve repair, and more. Additionally, we are equipped with a state-of-the-art Cath lab to support these advanced procedures.' This clinical achievement, like many others at S.L. Raheja Hospital Mumbai, reflect the hospital's unwavering commitment to compassionate care. It's milestones like these that allow the teams to keep pushing boundaries and touching lives – one patient at a time. About Fortis Healthcare Limited Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organizations in the country with 27 healthcare facilities, ~4,750 operational beds (including O&M facilities), and over 400 diagnostics centers (including JVs). The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with a global major and parent company – IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs over 23,000 people (including Agilus Diagnostics Limited) who share its vision of becoming the world's most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.
Mint
24-05-2025
- Health
- Mint
Meril Presents One-Year Results of LANDMARK RCT at EuroPCR 2025
Vapi, 24th May 2025– Meril Life Sciences today announced one-year results from its pivotal LANDMARK trial, presented during the prestigious Late-Breaking Trial session at EuroPCR 2025,one of the world's premier cardiology conferences held annually in Paris, LANDMARK trial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis. The Myval THV series demonstrated non-inferiority to contemporary THVs in terms of 1-year clinical efficacy composite endpoint (Myval THV Series: 13% vs. Contemporary THV: 13.1%, difference: -0.1%, one-sided 95% CI: 3.9%, Pnoninferiority < 0.0001). Additionally, in the composite endpoint of clinical efficacy combined with QoL, outcomes were comparable (Myval THV Series: 19.5% vs. Contemporary THVs: 22.7%, difference: -3.2%, 95% CI: -9.2 to 2.9, P=0.33). Hemodynamic parameters including effective orifice area (EOA), mean pressure gradient (PG), and incidence of moderate or greater aortic regurgitation remained stable and similar across all treatment arms. Survival rates were nearly identical (Myval THV Series: 92.8% vs. Contemporary THVs: 92.9%), and QoL improvements were comparable, reinforcing the overall safety and durability of the Myval THV series in everyday clinical use. Professor Patrick Serruys,Chairman and Study Director of the LANDMARKtrial, said:'This trial reflects a new era in comparative valve research. The meticulous design and adherence to VARC-3 standards, including QoL endpoints, mark it as a pivotal study. The results of the LANDMARKtrial represent a meaningful advancement for the global structural heart community—and most importantly, for patients receiving TAVI. The data not only validate the safety and efficacy of the Myval THV series, but also spotlight its adaptability to complex anatomies. This versatility is exactly what clinicians need to deliver precision care across a broad spectrum of patients.' Meril Professor Andreas Baumbach,Global Principal Investigator, said: 'The LANDMARK trial represents a significant step forward in TAVI research. For the first time, we've benchmarked Myval against both balloon-expandable and self-expanding platforms in a rigorous randomized setting. The one-year results demonstrates that the new generation Myval THV series can match global standards in safety and efficacy.' Mr. Sanjeev Bhatt,Senior Vice President – Corporate Strategy at Meril, said:'The LANDMARKtrial represents a significant milestone not just for Meril, but for the global TAVI community. The strong one-year results affirm the Myval THV series as a next-generation solution that delivers consistent safety, clinical efficacy, and improved quality of life across geographies. As the only head-to-head trial of its kind to include both balloon-expandable and self-expanding valves, it reinforces Myval THV series's versatility and real-world relevance for diverse patient anatomies and healthcare systems. At Meril, we are proud to contribute innovative, evidence-based technologies that are reshaping patient care and expanding access to advanced structural heart therapies worldwide.' The trial is designed to follow patients for a period of 10 years, aiming to generate long-term insights into clinical and echocardiographic outcomes, with a focus on valve durability and sustained performance. The LANDMARKtrial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis. The LANDMARKtrial was a prospective, randomized, multicenter, open-label, non-inferiority trial involving 768 patients who underwent Transcatheter Aortic Valve Implantation (TAVI) for the treatment of aortic stenosis. The first patient was enrolled in the LANDMARKtrial on 6 January 2021 and the last patient was enrolled on 5 December 2023. The trial included a total of 768 patients at 31 sites across 16 countries (Brazil, New Zealand, and some countries of Europe). The 30-day primary composite endpoints highlighting the safety and efficacy outcomes of the LANDMARKtrial have been successfully published in The Lancet and EuroIntervention, two of the most prestigious peer-reviewed medical journals. Meril is a global medical device company based in India, committed to advancing healthcare through innovation. With a strong focus on research and development, Meril delivers cutting-edge medtech solutions across more than 135 countries and has a robust presence through subsidiaries in the USA, Brazil, Europe, Asia, Africa, and Australia. Through partnerships, precision technology, and adherence to international quality standards, Meril is helping reshape the future of healthcare. Note to readers: This article is part of Mint's paid consumer connect Initiative. Mint assumes no editorial involvement or responsibility for errors, omissions, or content accuracy. Want to get your story featured as above? click here!
Business Standard
22-05-2025
- Health
- Business Standard
Meril Presents Successful LANDMARK RCT One-Year Results at Prestigious EuroPCR 2025
PRNewswire Vapi (Gujarat) [India], May 22: Meril Life Sciences announced one-year results from its pivotal LANDMARK trial, presented during the prestigious Late-Breaking Trial session at EuroPCR 2025, one of the world's premier cardiology conferences held annually in Paris, France. The LANDMARK trial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis. The Myval THV series demonstrated non-inferiority to contemporary THVs in terms of 1-year clinical efficacy composite endpoint (Myval THV Series: 13% vs. Contemporary THV: 13.1%, difference: -0.1%, one-sided 95% CI: 3.9%, Pnoninferiority < 0.0001). Additionally, in the composite endpoint of clinical efficacy combined with QoL, outcomes were comparable (Myval THV Series: 19.5% vs. Contemporary THVs: 22.7%, difference: -3.2%, 95% CI: -9.2 to 2.9, P=0.33). Hemodynamic parameters including effective orifice area (EOA), mean pressure gradient (PG), and incidence of moderate or greater aortic regurgitation remained stable and similar across all treatment arms. Survival rates were nearly identical (Myval THV Series: 92.8% vs. Contemporary THVs: 92.9%), and QoL improvements were comparable, reinforcing the overall safety and durability of the Myval THV series in everyday clinical use. Professor Patri c k Serruys, Chairman and Study Director of the LANDMARK trial, said: "This trial reflects a new era in comparative valve research. The meticulous design and adherence to VARC-3 standards, including QoL endpoints, mark it as a pivotal study. The results of the LANDMARK trial represent a meaningful advancement for the global structural heart community--and most importantly, for patients receiving TAVI. The data not only validate the safety and efficacy of the Myval THV series, but also spotlight its adaptability to complex anatomies. This versatility is exactly what clinicians need to deliver precision care across a broad spectrum of patients." Professor Andreas Baumbach, Global Principal Investigat or, said: "The LANDMARK trial represents a significant step forward in TAVI research. For the first time, we've benchmarked Myval against both balloon-expandable and self-expanding platforms in a rigorous randomized setting. The one-year results demonstrates that the new generation Myval THV series can match global standards in safety and efficacy." Mr. Sanjeev Bhatt, Senior Vice President - Corporate Strategy at Meril, said: "The LANDMARK trial represents a significant milestone not just for Meril, but for the global TAVI community. The strong one-year results affirm the Myval THV series as a next-generation solution that delivers consistent safety, clinical efficacy, and improved quality of life across geographies. As the only head-to-head trial of its kind to include both balloon-expandable and self-expanding valves, it reinforces Myval THV series's versatility and real-world relevance for diverse patient anatomies and healthcare systems. At Meril, we are proud to contribute innovative, evidence-based technologies that are reshaping patient care and expanding access to advanced structural heart therapies worldwide." The trial is designed to follow patients for a period of 10 years, aiming to generate long-term insights into clinical and echocardiographic outcomes, with a focus on valve durability and sustained performance. About THE LANDMARK TRIAL: The LANDMARK trial is the first randomized non-inferiority trial comparing the balloon-expandable Myval THV series with other contemporary balloon-expandable Sapien THV series and self-expandable Evolut THV series in patients with symptomatic severe aortic stenosis. The LANDMARK trial was a prospective, randomized, multicenter, open-label, non-inferiority trial involving 768 patients who underwent Transcatheter Aortic Valve Implantation (TAVI) for the treatment of aortic stenosis. The first patient was enrolled in the LANDMARK trial on 6 January 2021 and the last patient was enrolled on 5 December 2023. The trial included a total of 768 patients at 31 sites across 16 countries (Brazil, New Zealand, and some countries of Europe). The 30-day primary composite endpoints highlighting the safety and efficacy outcomes of the LANDMARK trial have been successfully published in The Lancet and EuroIntervention, two of the most prestigious peer-reviewed medical journals. About Meril Life Sciences: Meril is a global medical device company based in India, committed to advancing healthcare through innovation. With a strong focus on research and development, Meril delivers cutting-edge medtech solutions across more than 135 countries and has a robust presence through subsidiaries in the USA, Brazil, Europe, Asia, Africa, and Australia. Through partnerships, precision technology, and adherence to international quality standards, Meril is helping reshape the future of healthcare. Media Contact: media@
The Guardian
18-05-2025
- Health
- The Guardian
Over 400 with heart valve condition dying each year on NHS waiting list, research finds
Hundreds of patients with a deadly heart condition are dying every year while stuck on an NHS waiting list amid long delays for life-saving treatment, research reveals. About 300,000 people across the UK have aortic stenosis (AS), a serious but symptomless disease that weakens the heart's aortic valve, which helps push blood around the body. Although AS is often fatal, if detected and treated early, patients survive and regain a normal life. However, more than 400 people a year with AS die because they cannot get access fast enough on the NHS to a life-saving non-surgical procedure called transcatheter aortic valve implantation (Tavi), it has emerged. The disclosure has come from a survey of Tavi waiting times at the 35 specialist centres across the UK that provide the procedure. Heart doctors say the findings have exposed an 'unacceptable' mortality in Britain linked to the fact that it carries out far fewer Tavi procedures than many other European countries. Dr Jon Byrne, a cardiologist at King's College hospital in London, who initiated the research, said: 'Of all the people on the waiting list to have Tavi, 8% died before they received treatment – 8% is a big figure. That 8% is just over 400 patients a year. 'It's disturbing that this is happening. While some of those waiting die of other conditions, a significant proportion of them would have survived if they had been treated with Tavi.' The true death toll is much higher – probably about 800 a year, Byrne said – – because the survey only received data from 18 of the 35 centres. AS mainly affects people in their 70s, 80s and 90s. The research, by the medical group Valve for Life, also found that: A death rate as high as 20% at some hospitals which perform Tavi. The average waiting time for the procedure across the UK is 142 days – over 20 weeks – even though those with severe AS have a 50% risk of dying. White patients are more likely to undergo Tavi than those from ethnic minorities. In an article for the website Cardiology News that will be published on Monday, Byrne writes: 'These findings expose a growing crisis in access to Tavi across the UK. 'Despite the dedication and expertise of clinicians delivering exceptional care under increasing pressure, system inefficiencies, health inequalities and capacity constraints continue to put patients at risk.' The long waiting times for patients between being referred for Tavi and having it 'are leaving thousands of patients at risk', Byrne writes, in an opinion piece co-authored with Wil Woan, the executive director of the charity Heart Valve Voice. However, NHS England is understood to be developing plans to tackle mortality through a fast-track process under which the most urgent AS cases will undergo Tavi within eight weeks. Delays in accessing Tavi also put 'a significant strain on the NHS' because patients who go untreated end up needing to be admitted to hospital as emergencies, they add. Dr Sonya Babu-Narayan, the British Heart Foundation's clinical director, said: 'It's concerning to hear red flags raised about patients dying whilst waiting in situations in which a timely heart procedure may have saved their life. 'Nearly four out of 10 people are waiting more than 18 weeks [for treatment], which is too long when it comes to heart conditions, where timely care is critical. 'Long delays at this scale put people at risk of living in ill health or being unable to work due to heart failure which could have been avoided, and having their lives cut short.' The Department of Health and Social Care acknowledged that heart patients were facing long delays. A spokesperson for the department said: 'Because of the dire state of the NHS this government inherited, patients around the country, including those suffering from aortic stenosis, are waiting too long for treatment. 'Through our Plan for Change, we are delivering the investment and reform needed to get the NHS back on its feet and provide faster treatment for everyone who needs it, including those waiting for Tavi.'
The Guardian
18-05-2025
- Health
- The Guardian
‘She was so fit, so well': the heart patient who died before getting vital surgery
Sue Griffin was an active 68-year-old, retraining to become a nurse and indulging her love of horse riding, when she began to experience breathing difficulties, such as breathlessness. 'She was then diagnosed with asthma, and was going to see an asthma nurse,' her daughter Kirstie Campbell recalls. But despite treatment, it soon became apparent that Griffin's symptoms were not improving. 'She was getting more and more breathless as time was progressing,' Campbell says. 'She struggled doing things with the horses as well, she'd always done everything herself. She was getting fairly frustrated with herself, thinking that she was just turning into an old lady really quickly.' Griffin's breathing difficulties seriously progressed in 2021 and, after phoning 111, she was admitted to hospital and seen by the cardiology ward, where she was diagnosed with severe aortic stenosis. Her aortic valve, which controls blood moving from the heart to the body, was restricting blood flow. This causes it to become narrow, resulting in symptoms such as shortness of breath and chest pain. 'She stayed [in hospital] for a few days and it became apparent how serious her condition was,' Campbell says. 'It was made worse by the fact that she was anaemic. She was told she needed the procedure asap, but was still told to go home and wait for the hospital to be in contact within the next two weeks for an appointment.' The procedure, known as Transcatheter Aortic Valve Implantation (Tavi), is used to replace the valve without open heart surgery. Griffin was still waiting for her procedure to be scheduled when her condition suddenly declined, leading to her death in hospital. According to research by Valve for Life UK, up to 8.2% of patients on the elective Tavi waiting list die before being able to receive treatment, with some centres reporting a mortality rate as high as 20%. 'Everyone on the waiting list for this procedure needs it and is urgent, and they're all just a ticking timebomb, unfortunately,' Campbell says. 'It comes as no surprise that the figure is as high as it is, and I think it comes down purely to early diagnosis, and once they've got the diagnosis, they're already gravely ill,' Campbell says. 'What I'm finding really sad is that it's all been missed.' But, for Campbell, one of the hardest things to process is the fact that, if her mother had been able to have the procedure scheduled, the outcome may have been different. 'Knowing and listening to the surgeon who could have performed the surgery on my mum [during the inquest], and hearing him saying that there is a 1% mortality rate to this surgery that could have saved her life is extraordinary,' Campbell says. 'She was so fit, so well and so stoic, and she was my everything in my life. I worked with her for the last 40-odd years and spoke to her every day.' She added: 'Since then, I've lost myself as well because I don't have the one person that I can trust and belong to. It's hit me in a huge way that I didn't think was possible. Everything is more transient because I've lost the biggest person in my life and that's what I struggle to get over.'
